financetom
Business
financetom
/
Business
/
LeMaitre Vascular Q2 Earnings, Revenue Rise; Raises 2025 Guidance
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
LeMaitre Vascular Q2 Earnings, Revenue Rise; Raises 2025 Guidance
Aug 6, 2025 1:31 AM

04:06 AM EDT, 08/06/2025 (MT Newswires) -- LeMaitre Vascular ( LMAT ) reported Q2 earnings late Tuesday of $0.60 per diluted share, up from $0.52 a year earlier.

Four analysts polled by FactSet expected $0.57.

Revenue for the quarter ended June 30 was $64.2 million, compared with $55.8 million a year earlier.

For Q3, the company said it expects earnings of $0.54 to $0.59 per share on revenue of $61.2 million to $63.2 million. Analysts surveyed by FactSet expect earnings of $0.55 per share on revenue of $61.4 million.

The company raised its 2025 earnings guidance to $2.23 to $2.37 per share from $2.07 to $2.24 previously. It also increased its annual revenue guidance to $248 million to $254 million from $242 million to $249 million previously.

Analysts surveyed by FactSet expect earnings of $2.23 per share on revenue of $248.3 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
US FDA approves expanded use of Sarepta's Duchenne gene therapy
US FDA approves expanded use of Sarepta's Duchenne gene therapy
Jun 20, 2024
June 20 (Reuters) - The U.S. Food and Drug Administration allowed the expanded use of Sarepta Therapeutics' ( SRPT ) gene therapy for all patients with Duchenne muscular dystrophy aged four and above on Thursday. The agency gave traditional approval to patients four years and above who can walk, as well as accelerated approval for those who cannot. The company,...
Oceaneering International Unit Gets Umbilical Contract
Oceaneering International Unit Gets Umbilical Contract
Jun 20, 2024
05:42 PM EDT, 06/20/2024 (MT Newswires) -- Oceaneering International ( OII ) said late Thursday its Manufactured Products segment secured an umbilical contract worth about $50 million in revenue, with an unnamed domestic independent energy company. Oceaneering ( OII ) will supply about 27-kilometer of electro-hydraulic, steel tube dynamic umbilical for a project in the Gulf of Mexico. Manufacturing is...
Medalist Diversified REIT Plans Reverse, Forward Stock Splits on July 2
Medalist Diversified REIT Plans Reverse, Forward Stock Splits on July 2
Jun 20, 2024
05:39 PM EDT, 06/20/2024 (MT Newswires) -- Medalist Diversified REIT ( MDRR ) said late Thursday it would execute a 1-for-10 reverse split of its issued and outstanding common shares, which will be quickly followed by a 5-for-1 forward stock split. The reverse stock split is scheduled to take place at 5 pm ET on July 2, followed by the...
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours
Sarepta Therapeutics Gets Expanded US FDA Approval for Treatment of Duchenne Muscular Dystrophy; Shares Soar After Hours
Jun 20, 2024
05:41 PM EDT, 06/20/2024 (MT Newswires) -- Sarepta Therapeutics ( SRPT ) said late Thursday the US Food and Drug Administration approved the expansion of Elevidys to include patients ages 4 and above with Duchenne muscular dystrophy and a confirmed mutation in the DMD gene. Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients, the company said....
Copyright 2023-2026 - www.financetom.com All Rights Reserved